Replies to post #128326 on Biotech Values

[biomaven0]

Perhaps patients might also need to be tapered off the medication instead of discontinuing it suddenly in order to avoid a rebound effect.

That seems reasonable. Sort of issue where doctors get more experience with a drug.

But the letter does drive home that the drug is not hitting the underlying disease - really only providing symptomatic relief (which is not nothing).

What remains unknown also is how the drug will perform in some of the more prevalent conditions like polycythemia vera.

Peter